SUNY’s New Funding Fuels Binghamton Breakthroughs in AI Cancer Detection and Safer RNA Therapy

On September 14, the State University of New York announced a fresh round of seed funding for five campuses, and Binghamton University was right in the mix. A total of $400,000 will be parceled out, and two home‑grown research teams are set to benefit.

Professor Nancy Guo’s work centers on ClinSegAI, a machine‑learning platform that scans routine pathology slides for subtle biomarker patterns that often slip past the human eye. The idea is simple yet powerful: catch a cancer signal earlier, give doctors a longer window to intervene, and ultimately improve patient outcomes. Guo says the AI doesn’t replace pathologists—it augments them, acting like a second set of eyes that never tires.

Meanwhile, Associate Professor John Fetse is tinkering with the delivery vehicle for RNA‑based medicines. Existing therapies ride lipid nanoparticles that can irritate fat cells and cause unwanted side effects. Fetse’s twist involves threading specific amino acids into the lipid shell, a tweak that promises smoother sailing through the body and a lower risk of toxicity. If his approach holds up, patients could receive RNA drugs with fewer complications.

Both projects owe a lot to the SUNY Technology Accelerator Fund, a program the board touts as a bridge between campus labs and the marketplace. “SUNY research fuels economies and empowers communities,” the trustees wrote in a release, emphasizing how the money helps turn breakthroughs into real‑world products.

Binghamton President Anne D’Alleva echoed that sentiment, noting that the funding “could make a legitimate impact on medical‑care standards.” She praised Guo and Fetse for tackling health challenges that affect not just New Yorkers but people everywhere.

In practice, the AI model could be integrated into hospital pathology workflows within a few years, flagging high‑risk samples for follow‑up testing. Fetse’s refined lipid carriers, on the other hand, aim to make the next generation of RNA therapeutics—think gene‑editing medicines and personalized vaccines—safer and more efficient.

While the grant is just the beginning, the excitement on campus is palpable. Graduate students are already training the AI on thousands of slide images, and the chemistry lab is busy synthesizing the new lipid‑amino acid blends. If the early results keep up, Binghamton’s discoveries could soon move from the bench to bedside, offering hope to patients who need faster diagnoses and gentler treatments.